Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric…